Zollinger-Ellison syndrome and idiopathic hypersecretion are gastrointestinal hypersecretory conditions requiring long-term maintenance.
The safety and efficacy data for short-term treatment of these conditions with oral pantoprazole were previously published.
Dr Metz and colleagues extended the initial observations to 3 years.
The researchers' primary end point was the control of gastric acid secretion in the last hour before the next dose of oral pantoprazole.
| Almost all patients had a mean acid output rate less than 10 mmol per hour during treatment|
|Alimentary Pharmacology & Therapeutics|
Dose titration was permitted to a maximum of 240 mg per 24 hours.
The research team reported that 24 subjects completed the study.
The acid output of 28 of 34 subjects was controlled at initial enrolment.
The mean acid output rates were less than 10 mmol per hour throughout the 36 months of treatment for 90% to 100% of the patients.
The majority of the patients were controlled with bd doses of 40 or 80 mg pantoprazole at 36 months.
The researchers found that pantoprazole was generally well tolerated with minimal adverse events reported.
Dr Metz' team concluded, “Maintenance oral pantoprazole therapy up to 3 years at dosages of 40 to 120 mg bd was effective and well tolerated in patients with Zollinger-Ellison syndrome and other hypersecretory conditions.”